Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

Inclusion Criteria:

- Active chroidal neovascular AMD in at least one eye.

Exclusion Criteria:

- Retinal disease other than AMD that, in the investigator's opinion, would interfere
with safety or study conduct.

- Choroidal neovascularization due to a cause other than AMD.

- In the study eye, media opacity that, in the investigator's opinion, would interfere
with study conduct.

- Any disease or concomitant (or recent) medication expected to cause systemic
immunosuppression.

- History of meningococcal meningitis in the past 10 years, or any history of recurrent
meningitis.

- History of hospitalization for pneumococcal pneumonia within the past 3 years.

- History of serious systemic infection within the past 12 months.

- Any of the following treatments to the study eye within 7 days prior to study drug
dosing: ranibizumab (Lucentis), bevacizumab (Avastin), pegaptanib (Macugen), or other
VEGF inhibitor.

Other protocol-defined inclusion/exclusion criteria may apply